Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 263 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR Study Finds Disparities in Access to Opioids for Cancer Pain at... February 14, 2023 Ifosfamide May Be Treatment of Choice for Some People with Ewing... July 8, 2022 Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with... August 17, 2026 Your NCI: Top Priorities from AACR 2026 May 4, 2026 Load more HOT NEWS Pembrolizumab Plus Axitinib Outperforms Sunitinib in Patients with Metastatic Renal Cell... Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with... FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumours... Nursing Professor Who Used Her Breast Cancer Diagnosis as a Teaching...
